Your browser doesn't support javascript.
loading
Glucagonoma: Caso clínico
Gómez-Pérez, R; Cammarata-Scalisi, F; Petrosino-Tepedino, P; Arenas, A; Milano, M; Concho, H; Uzcátegui, Estrella; Ortiz, J; Parlapiano, D; Uzcátegui, L; Caraballo, Y; Ferrer, L.
  • Gómez-Pérez, R; s.af
  • Cammarata-Scalisi, F; s.af
  • Petrosino-Tepedino, P; s.af
  • Arenas, A; s.af
  • Milano, M; s.af
  • Concho, H; s.af
  • Uzcátegui, Estrella; s.af
  • Ortiz, J; s.af
  • Parlapiano, D; s.af
  • Uzcátegui, L; s.af
  • Caraballo, Y; s.af
  • Ferrer, L; s.af
Rev. venez. endocrinol. metab ; 2(3): 22-26, sep. 2004. ilus, graf, tab
Article in Spanish | LILACS-Express | LILACS | ID: lil-631124
RESUMEN
Objetivos. A propósito de un caso de glucagonoma, describir las principales características clínico-patológicas. Métodos. Se resume la historia clínica de una paciente a quien se le diagnóstico por inmunohistoquímica glucagonoma. Se revisa la literatura. Resultados. Paciente femenina de 54 años de edad, quien consulta por presentar dolor abdominal de moderada intensidad, mal definido, localizado a nivel de epigástrico con irradiación a mesogastrio; concomitantemente presenta pérdida de peso, poliuria, nicturia, estreñimiento severo y cifras de glucemias elevadas. Antecedentes de colecistectomía por litiasis biliar hace 3 años. En el examen físico refirió dolor a la palpación profunda a nivel de epigastrio y mesogastrio, resto del examen físico dentro de la normalidad. El estudio de laboratorio reveló una glucemia en ayunas de 325 mg/dL y postprandial de 531 mg/dL. Se inició tratamiento con insulina sin mejoría del control metabólico, por lo cual se aumento la dosis de insulina asociándola con un sensibilizador de la misma. Se realizó tomografía axial computarizada del abdomen observándose una tumoración ecomixta, bien delimitada, de 55.3 x 54.8 x 51.7 mm, localizada en el abdomen posterior, sin compromiso de la cabeza del páncreas. Debido al mal control metabólico y ante la sospecha de tumor funcionante del páncreas, se planteó la utilización de análogos de somatostatina, sin que pudiera ser utilizado por el costo del medicamento. La paciente fue llevada a quirófano realizándose recesión total de la tumoración. El control metabólico mejoró posterior a la cirugía. Los hallazgos histológicos fueron compatibles con células insulares pancreáticas con inmunohistoquímica positiva para glucagon. Conclusiones. El Glucagonoma es una entidad clínico-patológica poco frecuente pudiéndose presentar como una diabetes. La dificultad para un buen control metabólico de la diabetes y la pérdida incontrolada de peso pueden ser la clave para el diagnóstico.
ABSTRACT
Objectives. Based on a patient with a glucagonome, the clinical and histopathological characteristics of this tumor are described. Methods. A brief clinical history of a patient who was diagnosed to have a glucagonome, based on immunohistochemical analyses, is presented. Medical literature is reviewed about this entity. Results. A 54 years-old female patient, was admitted because of moderate, abdominal poorly localized pain, at the epigastric level, and referred to the mesogastric area. Concomitantly body-weight loss, polyuria, severe constipation, and hyperglycemia, were present. Cholecistectomy was performed because of cholelithiasis three years prior to admission. On physical examination, she presented pain with deep palpatory maneuvers at the epigastric and mesogastric areas. Without other particular findings. She presented fasting-blood glucose of 325 mg/dL, and 531 mg/dL in postprandial conditions. Insulin treatment was started, without improvement of the metabolic alteration. Consequently, insulin was administered associated with a sensitized, improving the glycemic control. An abdominal TAC was performed, revealing a mixed tumor, located in the posterior abdomen, well delimited, and measuring 55.3 x 54.8 x 51.7 mm. The head of the pancreas was not compromised. Due to difficulties in the control of the metabolic alterations, and under the suspicion of a pancreas functional tumor, it was considered the use of a somatostin analogous, which was never applied because of its high cost. Laparotomy was performed, and a total tumor resection was accomplished. The metabolic conditions improved after surgery. The histopathological findings were compatible with pancreatic insular cells, and immunohistochemically positive for glucagon. Conclusions. The glucagonome is rare clinical and pathological entity. It could be expressed as a diabetes. The difficulties to achieve a good metabolic control of the diabetes, and the continued weight loss, could be the clue for the diagnosis.

Full text: Available Index: LILACS (Americas) Language: Spanish Journal: Rev. venez. endocrinol. metab Journal subject: Nutritional Sciences / Endocrinology Year: 2004 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Language: Spanish Journal: Rev. venez. endocrinol. metab Journal subject: Nutritional Sciences / Endocrinology Year: 2004 Type: Article